Monitor ASCO presentation on May 30 for any additional data or commentary that could move the stock. Without new efficacy or safety endpoints, this filing is unlikely to be a near-term catalyst.
ONCY drugs
ONCY drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 22 $0.8100entry
- T+1 · 6mo ago 0.00%α −0.59% · $0.8100
- T+5 · 6mo ago +30.86%α +29.19% · $1.06
- T+20 · 5mo ago +14.81%α +16.23% · $0.9300
- T+60 · 3mo ago +4.30%α +1.11% · $0.8448
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oncolytics announced translational data from the GOBLET and AWARE-1 trials to be presented at ASCO 2026, showing pelareorep activates innate and adaptive immune responses and expands mutant KRAS-specific T cells. The press release contains no new financial information or definitive clinical outcomes, making this a routine scientific update.
Key Facts
- Data will be presented at ASCO 2026 (May 29-June 2) on pelareorep's mechanism of action.
- Translational analyses show pelareorep induces antiviral and anti-tumor immune responses.
- Expansion of mutant KRAS-specific T cell clones correlated with tumor volume reduction in pancreatic cancer.
- AWARE-1 breast cancer biopsies showed increased CXCL13 and tertiary lymphoid structure formation.
- No financial figures, guidance, or clinical endpoints were disclosed.
Financial Impact
No financial impact reported.
Risk Factors
- Translational data may not translate into clinical efficacy in ongoing trials.
- No update on cash runway or regulatory milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000035 |
| Document: asco2026pressrelease.htm | 0001129928-26-000035 |
| Document: 0001129928-26-000035-index-headers.html | 0001129928-26-000035 |
| Document: 0001129928-26-000035-index.html | 0001129928-26-000035 |
| Document: 0001129928-26-000035.txt | 0001129928-26-000035 |
Track record
32 reports on ONCY
3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers